Health · 32 views
New mRNA vaccine could reduce the recurrence and spread of skin cancer
Merck and Moderna announced a successful late-stage trial for a melanoma vaccine. NPR's Leila Fadel talks to Dr.
AI Summary
Merck and Moderna reported that a late‑stage trial of their mRNA melanoma vaccine met its primary endpoints, indicating it could lower the recurrence and spread of skin cancer. NPR interviewed Dr. Robert Vonderheide of Penn Medicine and the American Association for Cancer Research about the findings.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Immune changes linked to diabetes could guide development of new cancer treatmentsContinue reading
- Meal delivery apps could be driving us toward unhealthy choicesContinue reading
- Can an AI chatbot help women recognize heart disease?Continue reading
- RFK Jr. to ease access to unapproved peptides, draft policy statesContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow